Sign in
NRXP Stock Price, Chart, Stats & News
NRx Pharmaceuticals, Inc.
Save
65.08M
Market cap
–
Current P/E
34.25x
Forward P/E
NRXP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 50.61% |
Operating margin | -1322.04% |
Pretax margin | -2336.57% |
Net margin | -2336.57% |
Effective tax rate | – |
ROA | -220.92% |
ROE | 111.73% |
D/E | -0.04x |
Interest coverage ratio | -24.14x |
NRXP valuation
P/E | – |
P/S | 30.90x |
P/B | -4.36x |
P/CF | -4.92x |
P/FCF | -2.68x |
P/OCF | -4.92x |
PEG | -0.07x |
EV multiple | -1.35x |
About
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors.
Similar securities
Based on sector and market capitalization
Report issue